Prelude Therapeutics Incorporated — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Prelude is a clinical-stage oncology company and has not generated revenue. Financial figures below are in U.S. dollars; “million” is used for readability.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $25.0 million | $21.3 million | $46.8 million | $44.1 million |
| General and administrative expense | $7.4 million | $8.2 million | $14.7 million | $15.6 million |
| Total operating expenses | $32.4 million | $29.5 million | $61.5 million | $59.7 million |
| Net loss | $30.4 million | $27.4 million | $58.1 million | $56.8 million |
| Net loss per share, basic and diluted | $0.54 | $0.58 | $1.12 | $1.20 |
| Net cash used in operating activities | Not separately provided for quarter | $57.8 million | $40.4 million |
- At June 30, 2023, cash and cash equivalents were $26.4 million and marketable securities were $228.5 million, totaling approximately $255.0 million. Restricted cash was $4.0 million.
- Total assets were $280.6 million; total liabilities were $18.6 million; stockholders’ equity was $262.1 million. The filing reports no debt financing or credit facility.
- Accumulated deficit was $392.7 million. The company reported no operating profit or revenue, so operating margins are not meaningful.
- Management believes cash, cash equivalents, and marketable securities will fund operating expenses and capital expenditures for at least the next 12 months. The company expects continuing losses and says additional funding will be needed after that period.
Material changes and financing
- Q2 net loss increased $3.1 million year over year, mainly as higher R&D expense more than offset lower G&A expense. Six-month net loss increased $1.3 million year over year.
- R&D costs increased primarily with the timing of clinical research programs. Internal and personnel-related R&D costs rose; spending also began on PRT3789 and PRT3645. G&A declined, which management attributed to careful cost management.
- In Q2, Prelude raised $113.0 million gross, or $110.4 million net of offering costs, through common stock and pre-funded warrants. The warrants cover 12.9 million voting shares and had not been exercised by June 30. This financing increased liquidity but creates potential shareholder dilution.
- Operating cash use rose to $57.8 million from $40.4 million in the first half of 2022. Financing cash inflow of $111.1 million was largely from the Q2 offering. Investing cash use was $57.4 million, primarily reflecting purchases of marketable securities net of maturities.
Outlook, programs, and risks
- Management expects R&D expenses to increase significantly over coming years as clinical trials advance, and G&A costs to rise to support development and public-company requirements. No product revenue is expected in the foreseeable future.
- Management intended to provide program updates by year-end 2023 for PRT2527, PRT1419, PRT3645, and PRT3789. PRT3645 was expected to reach biologically active dose confirmation in Q4 2023; PRT3789 dose confirmation was expected in the first half of 2024. A newly nominated oral SMARCA2 degrader candidate was expected to have an IND filing in early 2024. These are forward-looking expectations, not reported outcomes.
- PRT2527 early solid-tumor data described manageable safety findings and target engagement; a hematologic malignancy Phase 1 study was ongoing and had expanded to global sites amid competitive U.S. recruitment.
- PRT1419 data described tolerability and target engagement, but no tumor reductions met response criteria. A hematologic malignancy study was ongoing, including combination arms.
- All candidates remain in development and require additional research, clinical testing, and regulatory approval. Key risks include trial outcomes, recruitment, competition, regulatory uncertainty, protection of intellectual property, and the need to obtain future financing. Equity financing could dilute shareholders; collaborations or licensing could require relinquishing valuable rights.
- The company expects the Chestnut Run lease for approximately 81,000 square feet to commence in Q3 2023. It had recorded $9.0 million of prepaid rent, with a 162-month initial lease term and estimated future rent payments. The filing also describes potential repayment obligations tied to Delaware grants if conditions are not met.
- Management reported no material changes to risk factors from the 2022 Form 10-K, no material legal proceedings, and effective disclosure controls as of June 30, 2023.
Important facts for investors to verify
- Whether clinical updates and dose-confirmation timelines for the four named programs were achieved, and what the data show on safety, efficacy, and target engagement.
- Current cash burn, investment balances, and runway relative to the stated minimum 12-month funding outlook.
- The potential dilution from the 12.9 million pre-funded warrants, alongside other outstanding options and equity awards.
- The timing and recognized costs of the Chestnut Run lease commencement, and compliance with conditions attached to Delaware grant funds.
- Drivers of the increase in operating cash use and R&D expense, including the unusually negative $0.4 million Q2 PRMT5 program expense shown in the program table; the filing does not clearly explain that negative value.